We are live on !
Find out more
VHCP Management III Portfolio holdings
AUM
$504M
Turnover
65.38%
1-Year Est. Return
683.12%
This Fund
S&P 500
This Quarter Est. Return
+363.21%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$504M
AUM Growth
+$342M
(+211%)
Cap. Flow
+$112M
Cap. Flow % of AUM
Cap. Flow %
22.32%
Top 10 Holdings %
Top 10 Hldgs %
90.41%
Holding
26
New
9
Increased
2
Reduced
5
Closed
8
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$70.7M |
| 2 |
89bio
ETNB
|
+$26.7M |
| 3 |
Relmada Therapeutics
RLMD
|
+$23.3M |
| 4 |
Adverum Biotechnologies
ADVM
|
+$8.34M |
| 5 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
+$8.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$15.9M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$9.8M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$7.76M |
| 5 |
Axsome Therapeutics
AXSM
|
+$2.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$7.12B
| $160M | 31.77% |
1,547,994
-63,335
| -4% | -$2.56M |
2019 Q1
3 quarters
|
|
|
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $119M | 23.54% |
2,516,242
+2,449,575
| +3,674% | +$70.7M |
2018 Q3
5 quarters
|
|
3
Milestone Pharmaceuticals
MIST
$89.8M
| $33.1M | 6.57% |
2,066,529
| – | – |
2019 Q2
2 quarters
|
|
|
4
Relmada Therapeutics
RLMD
$410M
| $30M | 5.95% |
+767,938
| New | +$23.3M |
2019 Q4
0 quarters
|
|
|
5
DELISTED
89bio
ETNB
| $25.2M | 5% |
+958,765
| New | +$26.7M |
2019 Q4
0 quarters
|
|
6
10x Genomics
TXG
$8.03B
| $22.9M | 4.54% |
300,000
| – | – |
2019 Q3
1 quarter
|
|
|
FTSV
7
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $20.3M | 4.04% |
+516,381
| New | +$8.29M |
2019 Q4
0 quarters
|
|
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $19.7M | 3.92% |
+575,000
| New | +$6.9M |
2019 Q4
0 quarters
|
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $14.6M | 2.9% |
+1,699,797
| New | +$6.07M |
2019 Q4
0 quarters
|
|
10
DELISTED
KalVista Pharmaceuticals
KALV
| $11M | 2.19% |
619,905
-17,979
| -3% | -$235K |
2018 Q3
5 quarters
|
|
|
11
DELISTED
Adverum Biotechnologies
ADVM
| $10.9M | 2.16% |
+94,623
| New | +$8.34M |
2019 Q4
0 quarters
|
|
12
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $10.8M | 2.15% |
1,254,041
+625,000
| +99% | +$3.51M |
2018 Q3
5 quarters
|
|
13
DELISTED
Mersana Therapeutics
MRSN
| $8.95M | 1.78% |
+62,456
| New | +$4.57M |
2019 Q4
0 quarters
|
|
|
MYOV
14
DELISTED
Myovant Sciences Ltd.
MYOV
| $7.07M | 1.4% |
+455,255
| New | +$4.59M |
2019 Q4
0 quarters
|
|
15
NextCure
NXTC
$28.9M
| $6.74M | 1.34% |
+9,974
| New | +$5M |
2019 Q4
0 quarters
|
|
|
OBSV
16
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $3.1M | 0.61% |
810,264
-349,525
| -30% | -$1.82M |
2018 Q3
5 quarters
|
|
|
17
Protagonist Therapeutics
PTGX
$9.02B
| $571K | 0.11% |
80,929
-991,419
| -92% | -$9.8M |
2018 Q4
4 quarters
|
|
|
BLPH
18
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $134K | 0.03% |
25,597
-135,551
| -84% | -$862K |
2018 Q3
5 quarters
|
|
|
19
BioCryst Pharmaceuticals
BCRX
$2.11B
| – | – |
-2,708,207
| Closed | -$7.76M | – |
|
20
Kiniksa Pharmaceuticals
KNSA
$7.13B
| – | – |
-277,137
| Closed | -$2.36M | – |
|
21
DELISTED
Kineta, Inc. Common Stock
KA
| – | – |
-1,580
| Closed | -$187K | – |
|
|
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-80,348
| Closed | -$2.48M | – |
|
23
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-23,131
| Closed | -$596K | – |
|
|
PRVL
24
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| – | – |
-4,408
| Closed | -$54K | – |
|
|
RARX
25
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-670,350
| Closed | -$15.9M | – |
|
Similar funds
LB
SC
VOAM
SC
VHCP Management III's Q4 2019 Portfolio in Review
As of Q4 2019, VHCP Management III held 26 positions worth $504M, up 211% from $162M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
VHCP Management III deployed $112M of net new capital in Q4 2019, opening 9 new positions and adding to 2 existing holdings. Its largest new stake was 89bio: 958,765 shares worth $25.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $9.8M trimmed.
- VHCP Management III's largest Q4 2019 buy was 89bio: 958,765 shares worth $25.2M.
- VHCP Management III added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $70.7M increase.
- VHCP Management III's biggest Q4 2019 reduction was Protagonist Therapeutics, cutting an estimated $9.8M.
- VHCP Management III fully exited Ra Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $15.9M.
- VHCP Management III's ten largest holdings make up 90% of its $504M portfolio in Q4 2019.
- VHCP Management III opened 9 new positions and closed 8 in Q4 2019.
- VHCP Management III's portfolio value rose 211% quarter-over-quarter to $504M.
Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.